PWPS
CRNX

Pinnacle Wealth Planning Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.96K Sell
186
-4
-2% -$149 ﹤0.01% 2201
2026
Q1 		$6.9K Buy
190
+135
+245% +$6.03K ﹤0.01% 2147
2025
Q4 		$2.56K Buy
+55
New +$2.45K ﹤0.01% 2429

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pinnacle Wealth Planning Services's CRNX Position: Q2 2026 in Review

Pinnacle Wealth Planning Services reduced its Crinetics Pharmaceuticals (CRNX) stake by 2.1% in Q2 2026, selling an estimated $149 and leaving 186 shares worth $6.96K. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Pinnacle Wealth Planning Services first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Pinnacle Wealth Planning Services held 186 shares of Crinetics Pharmaceuticals worth $6.96K as of Q2 2026.
  • Pinnacle Wealth Planning Services sold 4 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $149.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2201 holding.
  • Pinnacle Wealth Planning Services first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.